Samsung Bioepis’ European whitepaper on access to biosimilar medicines

South Korea’s Samsung Bioepis today published a whitepaper titled ‘Solving the Biosimilar Void in Europe’ that proposes policy recommendations to fully recognize the value of biosimilars and ensure a more sustainable market in Europe.

The company noted that biosimilars have played a significant role in alleviating the financial burden on the European healthcare system, having delivered 56 billion euros ($65.5 billion) in cumulative cost savings across Europe over the past 11 years (2013-2024). However, the current policy environment in Europe, particularly the post-launch pathways, is misaligned to incentivize biosimilar competition. With post-marketing challenges, on top of high development costs, many biologics will not face biosimilar competition at the point of loss of exclusivity (LoE) within the next decade, it said.